Also, a recent article showed that lowering CX3CR1 levels or partially inhibiting its activity in the brain might be a therapeutic strategy to increase neuronal Aβ clearance, reduce Aβ levels and delay progression of Alzheimer’s disease (Hickman et al., 2019). This evidence concerns the gene CX3CR1 and early-onset autosomal dominant Alzheimer disease.